Dies ist eine HTML Version eines Anhanges der Informationsfreiheitsanfrage 'The Vaccines Procurement Steering Committee & the Joint Negotiation Team'.

From:
To:
 (SG); 
 (SANTE)
Cc:
Subject:
CONFIDENTIAL - follow-up summary document
Date:
mardi 11 août 2020 05:47:52
Attachments:
RE Presentation of new data concerning mRNA1273 (543 KB).msg
CONFIDENTIAL - Moderna - European Commission - APA T&Cs 08.10.20 
.docx
Hi 
 
Hope this finds you well.
 
As promised, with the intent to provide 
 with a summary of the terms we have
been discussing over emails and calls, we put together a 3-page confidential document that can
be a helpful reference for the generation of your presentation to the steering board. I trust this
will be treated with utmost confidentiality.   Of note, we included
 
As it relates to the regulatory timelines, 
 exchanged emails last week and I
believe 
 received the level of detail he was looking for. I attached the last email from that
thread.
 
As it relates to the 
, I expect we would be in a position to send it back to you
tomorrow by EoD.
 
Please let us know if we can be of any help in the preparation of the presentation or the first
draft of the APA. Thank you for all the continued collaboration as we further refine the
framework of engagement and advance the APA discussions.
 
Please feel free to call 
 with any questions.
 
Best,
 
 
 
From:
@ec.europa.eu> 
Sent: Thursday, August 6, 2020 9:26 AM
To: 
@modernatx.com>; 
@modernatx.com>; 
@modernatx.com>
Subject: FW: C_2020_4192_F1_COMMISSION_DECISION_EN_V4_P1_1085037 (1).PDF - decision
+ agreement
 
Dear all – the Decision and Agreement setting up the whole EU approach. May be useful for your
team. 
 

From: 
 (SJ) 
@ec.europa.eu> 
Sent: Thursday, August 6, 2020 3:24 PM
To
 (SG) 
@ec.europa.eu>
Subject: C_2020_4192_F1_COMMISSION_DECISION_EN_V4_P1_1085037 (1).PDF -
decision + agreement
 
 
Please consider the environment before printing this email
Confidentiality notice and disclaimer: The information in this message and any attachments is intended for the
exclusive use of the addressee(s), is confidential and may be privileged or otherwise protected from disclosure.
Any review, retransmission, dissemination or other use of, or taking of any action in reliance upon, of any such
information by persons or entities other than the intended addressee(s) is prohibited. If you have received this
message in error and are not the intended addressee, please notify the sender immediately and delete this
message and any attachments from your system without reading or disclosing them. If you are not the intended
addressee, be advised that any use of the information in this message and any attachment is prohibited and may
be unlawful, and you must not copy this message or attachment or disclose the contents to any other person.